samedan logo
 
 
 
spacer
home > pmps > spring 2019 > digitising the chain
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Digitising the Chain

The pharmaceutical and medical supplies sector, like every other, has changed almost beyond recognition in the past decade, thanks to the development and availability of data-driven systems. For example, artificial intelligence is widely seen as the next frontier in R&D, helping to speed up clinical trials, improve their validity, and get drugs to market sooner.

Production, warehousing, and distribution have undergone a similar transition, with automation and data insights increasingly being used to speed up processes and improve traceability and compliance. Digital processes now impact every aspect of the modern supply chain, from Tier 1 drugs manufacturers to smallmedium enterprises supplying sterile packaging or components.

System Selection

Agile systems enable pharma companies to meet the requirements and challenges of a rapidly evolving sector. The availability of real-time data means production managers can make better informed decisions, moving from merely reporting what is happening on the shop floor to driving positive action. Its application is akin to researchers conducting clinical trials using data from multiple sources, such as wearable technology, rather than relying on limited and/or historic results to deliver more rigorous results faster.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Rod Schregardus is a Consultant Manager at pharma software expert, Access Group. Specialising in global new business for Access’ advanced planning and scheduling software, Access Orchestrate, Rod boasts over 20 years in the manufacturing industry and works with pharma companies across the world.
spacer
Rod Schregardus
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)

- The biotech companies 3P Biopharmaceuticals and Toleranzia collaborate for that MG treatment - MG is an orphan disease which has a major unmet medical need and a large market potential - The drug candidate,TOL2, has already achieved several positive preclinical results
More info >>

White Papers

R&D to Product: How to Reduce Costly Scale-Up Problems

Natoli Engineering Company, Inc.

When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement